Aging is not officially classified as a disease, but the question is far from settled. The debate sits at the intersection of biology, philosophy, and regulatory policy, and the answer you get depends heavily on who you ask and how they define “disease.” What makes this more than an academic argument is that the classification has real consequences for research funding, drug development, and how society treats older adults.
What the Biology Actually Shows
At a cellular level, aging looks a lot like a disease process. Researchers have identified twelve distinct biological mechanisms, known as the hallmarks of aging, that drive physical decline: DNA damage accumulation, shortening of the protective caps on chromosomes, changes to how genes are switched on and off, the buildup of misfolded proteins, failing cellular recycling systems, disrupted nutrient signaling, declining energy production in cells, the accumulation of zombie-like cells that refuse to die, exhaustion of stem cell reserves, breakdowns in cell-to-cell communication, chronic low-grade inflammation, and imbalances in gut bacteria. Each of these can be traced to specific molecular changes, studied in a lab, and potentially targeted with interventions.
This is the foundation of the “aging is a disease” argument. A disease, by standard medical definition, is any abnormality of bodily structure or function other than those arising directly from physical injury. Aging clearly involves harmful changes to bodily structure and function. It has identifiable causes at the cellular level. It produces recognizable signs and symptoms. By that definition, aging checks every box.
The Case for Calling It a Disease
Proponents argue that labeling aging as “natural” creates a kind of fatalism that holds back medicine. If aging is just something that happens, there’s less urgency to treat it. Reclassifying it as a disease, or at least a treatable condition, would open the door to regulatory frameworks that allow drugs to be developed and approved specifically to slow or reverse the aging process. Currently, the FDA does not recognize aging itself as a condition that drugs can treat, which means any anti-aging therapy has to be framed as targeting a specific age-related disease like heart failure or Alzheimer’s instead.
The philosopher David Gems has argued that aging’s universality doesn’t disqualify it from being a disease. It simply makes it a “special form of disease.” After all, dental cavities are nearly universal, yet no one hesitates to call them a disease and treat them. The key distinction proponents draw is between aging as the passage of time and aging as physiological decline. The passage of time isn’t undesirable. The loss of physical and mental capacity that accompanies it most certainly is.
There’s also a regulatory argument. Recognizing aging as a disease would shift anti-aging therapies from the looser oversight applied to cosmetics and supplements into the more rigorous framework governing disease treatment and prevention. That would mean more clinical trials, better safety data, and treatments held to a higher evidence standard before reaching consumers.
The Case Against
Critics push back on several fronts. The most fundamental objection is philosophical: aging is a process inherent to all living things. Calling it a disease creates a paradox. How do you diagnose and cure something that is inseparable from life itself? Aging can only be stopped by eliminating metabolism entirely, which is to say, by eliminating what makes something alive.
There’s also a concern about confusing levels of analysis. The fact that cells deteriorate over time doesn’t automatically mean that the whole-person experience of aging is a pathology. Human aging involves losses, yes, but also gains in experience, perspective, and adaptation. Critics argue it’s not logical to take what happens at the molecular level and extrapolate it to the full complexity of a human life. Children grow and develop before reaching adulthood, but we don’t describe childhood development as a disease process, even though it involves dramatic biological change.
A more practical critique targets the hallmarks of aging themselves. Even researchers who defend the disease framework acknowledge that healthy lifestyles can prevent or delay many of these cellular changes. That suggests unhealthy behaviors are the risk factors, not aging itself. If someone who exercises, eats well, and sleeps enough can reach old age without many of the hallmarks, then the hallmarks may reflect lifestyle-driven damage more than an inevitable disease process.
Some evolutionary biologists frame the issue differently still. Our species evolved under selection pressures favoring successful reproduction as young adults, not health into old age. Longevity as a population-wide norm is extremely recent in human history. From this view, age-related conditions like metabolic syndrome aren’t failures of the body. They’re the predictable outcome of normally adaptive biology placed in an environment we weren’t evolved to live in: one with abundant calories, minimal physical demands, and decades of life beyond our reproductive years. That’s not disease. That’s a mismatch.
Where Official Classifications Stand
The World Health Organization waded into this debate when it proposed including “old age” as a diagnostic category in ICD-11, the international system used to classify diseases and health conditions. The term was intended to replace “senility,” a code that had existed in the previous version. But pushback was swift. Critics argued the label was reductive and could fuel ageism. The WHO ultimately retracted “old age” as a category title and replaced it with “ageing associated decline in intrinsic capacity,” a phrase that acknowledges functional decline without calling aging itself a disease. The word “pathological” was also dropped as a descriptor for aging and replaced with “biological.”
This compromise reflects the tension in the field. Official bodies are increasingly willing to recognize that biological aging involves measurable, harmful changes. But they stop short of labeling the entire process a disease.
Why the Label Matters for Research
The classification question isn’t just philosophical. It directly shapes what kinds of treatments can be developed and how they get approved. The TAME trial (Targeting Aging with Metformin) is the most prominent example. This clinical trial was designed with input from the FDA to test whether a widely used diabetes drug can slow aging itself, rather than just treating individual age-related diseases. The trial’s primary endpoints were shaped specifically to create regulatory precedent for aging-relevant drug indications.
If a trial like TAME succeeds, it could establish a framework where drugs are approved to target aging as a biological process. That would be a first. Right now, a company developing a drug that slows cellular aging would have to pick a specific disease (cancer, heart disease, dementia) and run a trial against that single condition, even if the drug’s real mechanism is much broader.
The Economic Stakes
The financial implications of treating aging as a targetable condition are enormous. One widely cited economic analysis estimated that delaying the biological aging process would generate roughly $7.1 trillion in social value over 50 years, measured in additional quality-adjusted years of life. That figure doesn’t even include the cognitive benefits that might come from keeping brains healthier longer.
The picture isn’t entirely rosy, though. Delayed aging would also mean more people living longer, which increases government spending on retirement and healthcare programs. By 2060, one projection found that delayed aging would add nearly $420 billion in annual entitlement costs compared to current trends, with about 70% of that increase coming from Medicare and Medicaid. However, the same analysis showed these costs could be fully offset by modest policy adjustments, such as raising the retirement age in step with increased healthspan. With that fix in place, the additional entitlement spending effectively disappears, even with a much larger older population.
The economic case, then, isn’t really about whether society can afford to treat aging. It’s about whether the social systems around retirement and healthcare can adapt quickly enough to keep pace with longer, healthier lives.
A Question That Shapes How We Think About Getting Older
Underneath the biology and policy debates is a deeper question about what kind of relationship we want to have with aging. If aging is a disease, then every older person is, by definition, sick. Critics worry this framing strips dignity from later life and reinforces ageism. If aging is natural, though, there’s a risk of complacency, of accepting preventable suffering as inevitable simply because it’s common.
The most productive framing may be the one the field is slowly converging on: aging is not a disease in the traditional sense, but many of its biological components are targetable, treatable, and worth taking seriously as medical problems. You don’t have to call the entire arc of human life a pathology to justify treating the specific molecular processes that make the last decades harder than they need to be.